| Name | Title | Contact Details |
|---|
Blue Giant Equipment Corporation is a prominent global manufacturer and distributor of loading dock systems and material handling equipment, headquartered in Toronto, Ontario, Canada. Founded in 1963 by Kurt Larsen, the company has celebrated over 60 years of innovation in the industry. Blue Giant began with mechanical dock levelers and hand pallet trucks, later expanding its offerings to include intelligent dock controls and air-powered loading dock equipment. The company provides a wide range of products, including loading dock systems, material handling equipment, HVLS fans, and ergonomic lift assist solutions. Their innovative Blue Genius Connect control panel enhances the management of loading dock operations. Blue Giant has received multiple awards for its products, including recognition in the Professional Door Dealer magazines "Best of Business Dealers Choice Poll" and a Bronze Award from Plant Engineering magazine. With a commitment to growth, Blue Giant relocated its headquarters in 2017 to a larger facility in Mississauga, Ontario, reflecting its dedication to expanding its capabilities in the material handling sector.
Kee Safety, Inc. is one of the worlds leading Safety Solutions Suppliers. We have been providing industry specific solutions such as railings, barriers, perimeter protection, fall prevention and many other applications since 1934. From Machine Guards to Roof Edge Fall Protection, Guardrailing to Pedestrian Barriers, Shop Fitting to Childrens Playgrounds, Kee Safety has supplied the answer to many problems with safe, reliable, cost effective and durable solutions. Please visit our website for more information.
BNP Paribas is a leading bank in Europe with an international reach. It has a presence in 65 countries, with more than 190,000 employees, including more than 145,000 in Europe. BNP Paribas holds leading positions in its three major operating divisions: ⚆ Commercial, Personal Banking & Services for all the Groups retail banking networks and several specialised businesses, including BNP Paribas Personal Finance and Arval; ⚆ Investment & Protection Services for savings, investment and protection solutions; ⚆ Corporate & Institutional Banking, which is focused on corporate and institutional clients. The Group helps all its clients (individuals, community associations, entrepreneurs, SMEs, corporates and institutional clients) to realise their projects through solutions spanning financing, investment, savings and protection insurance. In Europe, the Group has four domestic markets (Belgium, France, Italy and Luxembourg) and BNP Paribas Personal Finance is the European leader in consumer lending. BNP Paribas is rolling out its integrated retail-banking model in Mediterranean countries, in Turkey, in Eastern Europe and a large network in the western part of the United States. In its Corporate & Institutional Banking and Investment & Protection Services activities, BNP Paribas also enjoys top positions in Europe, a strong presence in the Americas as well as a solid and fast-growing business in Asia-Pacific. To learn more about our social media terms and Data Protection Notice: https://group.bnpparibas/en/data-protection
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.